Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022


#163787

47pages

GlobalData

$ 6995

In Stock

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Ferring’s Firmagon is a synthetic peptide that targets the LHRH receptor. It is differentiated from its competitors in that it acts as an LHRH receptor antagonist rather than as an agonist (that is, an LHRH analog). Firmagon is prescribed for patients with advanced prostate cancer and is administered monthly as a subcutaneous injection. The binding of Firmagon to the LHRH receptor rapidly results in decreased testosterone production without the testosterone flare that is characteristic of treatment with LHRH receptor agonists.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Firmagon including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Firmagon for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Firmagon performance 
  • Obtain sales forecast for Firmagon from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)